SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts

A Proportional Hazards Model for the Subdistribution of a Competing Risk

Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290 · see citing works

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933 · see citing works

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Vardiman, J., Thiele, J., Arber, D., Brunning, R., Borowitz, M., Porwit, A., Harris, N., Beau, M. L. L., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,837 · see citing works

Proposals for the classification of the myelodysplastic syndromes

Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,619 · see citing works

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 3,181 · see citing works

The World Health Organization (WHO) classification of the myeloid neoplasms

Vardiman, J. W., Harris, N. L., & Brunning, R. D. (2002) · Blood · doi:10.1182/blood-2002-04-1199 · Cited by 2,191 · see citing works

Frequent pathway mutations of splicing machinery in myelodysplasia

Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029 · see citing works

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311347 · Cited by 2,003 · see citing works

Clinical and biological implications of driver mutations in myelodysplastic syndromes

Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C. J., Ellis, P., Wedge, D. C., Pellagatti, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-518886 · Cited by 1,832 · see citing works

Mutation in <i>TET2</i> in Myeloid Cancers

Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776 · see citing works

Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia

Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., Kennedy, J. A., Schimmer, A. D., Schuh, A. C., Yee, K. W., et al. (2014) · Nature · doi:10.1038/nature13038 · Cited by 1,443 · see citing works

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

Ko, M., Huang, Y., Jankowska, A. M., Pape, U. J., Tahiliani, M., Bandukwala, H. S., An, J., Lamperti, E. D., Koh, K. P., Ganetzky, R. D., et al. (2010) · Nature · doi:10.1038/nature09586 · Cited by 1,294 · see citing works

Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts

Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222 · see citing works

Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes

Malcovati, L., Germing, U., Kuendgen, A., Porta, M. G. D., Pascutto, C., Invernizzi, R., Giagounidis, A. A. N., Hildebrandt, B., BERNASCONI, P. P., Knipp, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5696 · Cited by 1,029 · see citing works

Acquired mutations in TET2 are common in myelodysplastic syndromes

Langemeijer, S. M. C., Kuiper, R. P., Berends, M., Knops, R., Aslanyan, M. G., Massop, M., Stevens-Linders, E., van Hoogen, P., van Kessel, A. G., Raymakers, R. A. P., et al. (2009) · Nature Genetics · doi:10.1038/ng.391 · Cited by 755 · see citing works

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

Malcovati, L., Hellström‐Lindberg, E., Bowen, D., Adès, L., Čermák, J., del Cañizo, C., Porta, M. G. D., Fenaux, P., Gattermann, N., Germing, U., et al. (2013) · Blood · doi:10.1182/blood-2013-03-492884 · Cited by 667 · see citing works

Kaplan—meier, marginal or conditional probability curves in summarizing competing risks failure time data?

PEPE, M. S., & Mori, M. (1993) · Statistics in Medicine · doi:10.1002/sim.4780120803 · Cited by 617 · see citing works

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

Rumi, E., Pietra, D., Ferretti, V. V., Klampfl, T., Harutyunyan, A. S., Feenstra, J. D. M., Them, N. C. C., Berg, T., Elena, C., Casetti, I. C., et al. (2013) · Blood · doi:10.1182/blood-2013-11-539098 · Cited by 602 · see citing works

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Malcovati, L., Papaemmanuil, E., Bowen, D., Boultwood, J., Porta, M. G. D., Pascutto, C., Travaglino, E., Groves, M. J., Godfrey, A. L., Ambaglio, I., et al. (2011) · Blood · doi:10.1182/blood-2011-09-377275 · Cited by 496 · see citing works

Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis

Suragani, R. N. V. S., Cadena, S. M., Cawley, S. M., Sako, D., Mitchell, D., Li, R., Davies, M. V., Alexander, M. J., Devine, M., Loveday, K. S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3512 · Cited by 452 · see citing works

Distinct haematological disorder with deletion of long arm of No. 5 chromosome

BERGHE, H. V. D., Cassiman, J., David, G., Fryns, J., Michaux, J., & SOKAL, G. (1974) · Nature · doi:10.1038/251437a0 · Cited by 442 · see citing works

The genetic basis of myelodysplasia and its clinical relevance

Cazzola, M., Porta, M. G. D., & Malcovati, L. (2013) · Blood · doi:10.1182/blood-2013-09-381665 · Cited by 345 · see citing works

Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts

Mufti, G. J., Bennett, J. M., Goasguen, J., Bain, B. J., Baumann, I., Brunning, R. D., Cazzola, M., Fenaux, P., Germing, U., Hellström‐Lindberg, E., et al. (2008) · Haematologica · doi:10.3324/haematol.13405 · Cited by 337 · see citing works

Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia

Such, E., Germing, U., Malcovati, L., Cervera, J., Kuendgen, A., Porta, M. G. D., Nomdedeu, B., Arenillas, L., Luño, E., Xicoy, B., et al. (2013) · Blood · doi:10.1182/blood-2012-08-452938 · Cited by 320 · see citing works

Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo

Woll, P. S., Kjällquist, U., Chowdhury, O., Doolittle, H., Wedge, D. C., Thongjuea, S., Erlandsson, R., Ngara, M., Anderson, K., Deng, Q., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.036 · Cited by 317 · see citing works

An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia

Dussiot, M., Maciel, T. T., Fricot, A., Chartier, C., Negre, O., Veiga, J., Grapton, D., Paubelle, E., Payen, E., Beuzard, Y., et al. (2014) · Nature Medicine · doi:10.1038/nm.3468 · Cited by 279 · see citing works

Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia

Malcovati, L., Papaemmanuil, E., Ambaglio, I., Elena, C., Gallì, A., Porta, M. G. D., Travaglino, E., Pietra, D., Pascutto, C., Ubezio, M., et al. (2014) · Blood · doi:10.1182/blood-2014-03-560227 · Cited by 251 · see citing works

SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value

Patnaik, M. M., Lasho, T. L., Hodnefield, J. M., Knudson, R. A., Ketterling, R. P., Garcia‐Manero, G., Steensma, D. P., Pardanani, A. D., Hanson, C. A., & Tefferi, A. (2011) · Blood · doi:10.1182/blood-2011-09-377994 · Cited by 201 · see citing works

Mutant p53 reactivation by small molecules makes its way to the clinic

Bykov, V. J. N., & Wiman, K. G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.04.017 · Cited by 180 · see citing works

Biological validation that SF3b is a target of the antitumor macrolide pladienolide

Yokoi, A., Kotake, Y., Takahashi, K., Kadowaki, T., Matsumoto, Y., Minoshima, Y., Sugi, N. H., Sagane, K., Hamaguchi, M., Iwata, M., et al. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08387.x · Cited by 176 · see citing works

Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms

Cazzola, M., Rossi, M., & Malcovati, L. (2012) · Blood · doi:10.1182/blood-2012-09-399725 · Cited by 151 · see citing works

Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

Malcovati, L., Porta, M. G. D., Pietra, D., Boveri, E., Pellagatti, A., Gallì, A., Travaglino, E., Brisci, A., Rumi, E., Passamonti, F., et al. (2009) · Blood · doi:10.1182/blood-2009-05-222331 · Cited by 144 · see citing works

Chronic Refractory Anemia with Sideroblastic Bone Marrow: A Study of Four Cases

Björkman, S. E. (1956) · Blood · doi:10.1182/blood.v11.3.250.250 · Cited by 140 · see citing works

Morphological evaluation of monocytes and their precursors

Goasguen, J.-E., Bennett, J. M., Bain, B. J., Vallespı́, T., Brunning, R. D., Mufti, G. J., & for the International Working Group on Morphology of Myelodysplastic Syndrome (IWGM-MDS) (2009) · Haematologica · doi:10.3324/haematol.2008.005421 · Cited by 125 · see citing works

Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis

Broséus, J., Alpermann, T., Wulfert, M., Florensa, L., Jeromin, S., Lippert, É., Rozman, M., Lifermann, F., Großmann, V., Haferlach, T., et al. (2013) · Leukemia · doi:10.1038/leu.2013.120 · Cited by 94 · see citing works

First-order rate-determining aggregation mechanism of p53 and its implications

Wang, G., & Fersht, A. R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211557109 · Cited by 71 · see citing works

Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1

Ambaglio, I., Malcovati, L., Papaemmanuil, E., Laarakkers, C. M., Porta, M. G. D., Gallì, A., Vià, M. D., Bono, E. B., Ubezio, M., Travaglino, E., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.077446 · Cited by 59 · see citing works

Comparison of Splicing Factor 3b Inhibitors in Human Cells

Gao, Y., Vogt, A., Forsyth, C. J., et al. (2012) · ChemBioChem · doi:10.1002/cbic.201200558 · Cited by 45 · see citing works

ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study

Platzbecker, U., Germing, U., Giagounidis, A. A. N., Goetze, K. S., Kiewe, P. M., Mayer, K. T., Ottman, O. G., Radsak, M. P., Wolff, T. E., Haase, D. T., et al. (2014) · Blood · doi:10.1182/blood.v124.21.411.411 · Cited by 12 · see citing works

Cancer-Associated Mutations in SF3B1 Exhibit Neomorphic Splicing Activity and Block Erythroid Differentiation

Buonamici, S., Perino, S., Lim, K., et al. (2014) · Blood · doi:10.1182/blood.v124.21.4615.4615 · Cited by 1 · see citing works

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119 · see citing works

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

Bernard, E., Tuechler, H., Greenberg, P. L., Hasserjian, R. P., Arango Ossa, J. E., Nannya, Y., Devlin, S. M., Creignou, M., Pinel, P., Monnier, L., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200008 · Cited by 867 · see citing works

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

Platzbecker, U., Germing, U., Götze, K. S., Kiewe, P., Mayer, K., Chromik, J., Radsak, M., Wolff, T., Zhang, X., Laadem, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30615-0 · Cited by 292 · see citing works

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

for the International Working Group for MDS Molecular Prognostic Committee, Haase, D., Stevenson, K. E., Neuberg, D., Maciejewski, J. P., Nazha, A., Sekeres, M. A., Ebert, B. L., Garcia-Manero, G., Haferlach, C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0351-2 · Cited by 259 · see citing works

Iron-sulfur cluster deficiency can be sensed by IRP2 and regulates iron homeostasis and sensitivity to ferroptosis independent of IRP1 and FBXL5

Terzi, E. M., Sviderskiy, V. O., Alvarez, S. W., Whiten, G. C., & Possemato, R. (2021) · Science Advances · doi:10.1126/sciadv.abg4302 · Cited by 195 · see citing works

Ineffective erythropoiesis and regulation of iron status in iron loading anaemias

Camaschella, C., & Nai, A. (2016) · British Journal of Haematology · doi:10.1111/bjh.13820 · Cited by 172 · see citing works

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Montalban-Bravo, G., Kanagal-Shamanna, R., Benton, C. B., Class, C. A., Chien, K. S., Sasaki, K., Naqvi, K., Alvarado, Y., Kadia, T. M., Ravandi, F., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001101 · Cited by 133 · see citing works

Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction

Fujihara, K. M., Zhang, B. Z., Jackson, T. D., Ogunkola, M. O., Nijagal, B., Milne, J. V., Sallman, D. A., Ang, C.-S., Nikolic, I., Kearney, C. J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm9427 · Cited by 103 · see citing works

A variant erythroferrone disrupts iron homeostasis in <i>SF3B1</i> -mutated myelodysplastic syndrome

Bondu, S., Alary, A.-S., Lefèvre, C., Houy, A., Jung, G., Lefebvre, T., Rombaut, D., Boussaid, I., Bousta, A., Guillonneau, F., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav5467 · Cited by 85 · see citing works

Current and emerging strategies for management of myelodysplastic syndromes

Saygin, C., & Carraway, H. E. (2021) · Blood Reviews · doi:10.1016/j.blre.2020.100791 · Cited by 70 · see citing works

The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution

Singhal, D., Wee, L. Y. A., Kutyna, M. M., Chhetri, R., Geoghegan, J., Schreiber, A. W., Feng, J., Wang, P. P.-S., Babic, M., Parker, W. T., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0479-8 · Cited by 62 · see citing works

Risk and timing of cardiovascular death among patients with myelodysplastic syndromes

Brunner, A. M., Blonquist, T. M., Hobbs, G. S., Amrein, P. C., Neuberg, D. S., Steensma, D. P., Abel, G. A., & Fathi, A. T. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010165 · Cited by 63 · see citing works

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes

de Swart, L., Reiniers, C., Bagguley, T., van Marrewijk, C., Bowen, D., Hellström-Lindberg, E., Tatic, A., Symeonidis, A., Huls, G., Cermak, J., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.171884 · Cited by 48 · see citing works

Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in <i>SF3B1</i> -Mutant Myelodysplastic Syndromes With Ringed Sideroblasts

Adema, V., Ma, F., Kanagal-Shamanna, R., Thongon, N., Montalban-Bravo, G., Yang, H., Peslak, S. A., Wang, F., Acha, P., Sole, F., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0220 · Cited by 20 · see citing works

Myelodysplastic Syndromes (MDS)

Madanat, Y. F., & Sekeres, M. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-97873-4_27

Erythroleukemia and Myelodysplastic Syndromes: An Historical Appraisal and aPersonalView

Michiels, J. J. (1993) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199309148500 · Cited by 9 · see citing works

Finger length and distal finger extent patterns in humans

Peters, M., Mackenzie, K., & Bryden, P. J. (2002) · American Journal of Physical Anthropology · doi:10.1002/ajpa.10029 · Cited by 164 · see citing works

Infections in myelodysplastic syndromes

Toma, A., Fenaux, P., Dreyfus, F., & Cordonnier, C. (2012) · Haematologica · doi:10.3324/haematol.2012.063420 · Cited by 119 · see citing works

Finger length and distal finger extent patterns in humans

Peters, M., Mackenzie, K., & Bryden, P. J. (2002) · American Journal of Physical Anthropology · doi:10.1002/ajpa.10029.abs · Cited by 12 · see citing works